Literature DB >> 2142395

Endocrine effects of a 24-hour intravenous infusion of interleukin-2 in the immunotherapy of cancer.

P Lissoni1, S Barni, C Archili, G Cattaneo, F Rovelli, A Conti, G J Maestroni, G Tancini.   

Abstract

Several experiments have demonstrated that there is a relationship between neuroendocrine and immune systems. Despite these interesting findings, only few studies have been performed up to now to evaluate the possible importance of neuroimmune interactions in influencing the biological efficacy and toxicity of cancer immunotherapy with IL-2. To analyze the effects of IL-2 on endocrine secretions, we have measured by RIA serum levels of cortisol, beta-endorphin, GH, PRL and of the pineal hormone melatonin in metastatic renal cancer patients, treated with 5-day courses of IL-2 at a daily dose of 3 x 10(6) U/m2, given through a 24-hour intravenous infusion. Six IL-2 courses were evaluated, by collecting blood samples at 4-hour intervals for 24 hours and by comparing the hormonal values with those observed in baseline conditions. Both cortisol and beta-endorphin mean values significantly increased during IL-2 infusion. GH and PRL also increased, but not in a significant manner. Finally, melatonin mean levels significantly decreased during the infusion. The IL-2-induced effects on cortisol, beta-endorphin and melatonin resulted in a complete abolition of their physiological circadian rhythm. These results show that IL-2 infusion induces important changes in endocrine secretions. Because of the immunosuppressive effect of cortisol and the stimulatory one of melatonin, their changes during IL-2 infusion might influence the biological activity of immunotherapy itself. Further studies will be required to define better the clinical importance of IL-2 induced hormonal changes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2142395

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour.

Authors:  P Lissoni; S Barni; V Fossati; A Ardizzoia; M Cazzaniga; G Tancini; F Frigerio
Journal:  Support Care Cancer       Date:  1995-05       Impact factor: 3.603

2.  Interleukin-2 drives cortisol secretion in an age-, dose-, and body composition-dependent way.

Authors:  Ferdinand Roelfsema; Peter Y Liu; Rebecca Yang; Paul Takahashi; Johannes D Veldhuis
Journal:  Endocr Connect       Date:  2020-07       Impact factor: 3.335

3.  Interleukin-2 Transiently Inhibits Pulsatile Growth Hormone Secretion in Young but not Older Healthy Men.

Authors:  Ferdinand Roelfsema; Rebecca Yang; Johannes D Veldhuis
Journal:  J Clin Endocrinol Metab       Date:  2021-09-27       Impact factor: 6.134

4.  A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.

Authors:  P Lissoni; S Barni; G Tancini; A Ardizzoia; G Ricci; R Aldeghi; F Brivio; E Tisi; F Rovelli; R Rescaldani
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.